Article Text

Download PDFPDF
The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
  1. A. Ph. Makar*,
  2. R. Holm,
  3. G. B. Kristensen*,
  4. J. M. Nesland and
  5. C. G. TropÉ*
  1. * Departments of Gynecologic Oncology and
  2. Pathology, The Norwegian Radium Hospital, Oslo, Norway
  1. Address for correspondence: G. B. Kristensen, Department of Gynecologic Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.


The expression of c-erbB-2 oncogene has been studied in 74 formalin fixed paraffin embedded invasive epithelial ovarian malignancies using a monoclonal c-erbB-2 protein antibody. Only four (5.4%) tumors showed membrane immunostaining. FIGO stage, size of residual disease after primary surgery, histologic type and tumor grade, were identified by the log rank test as prognostic factors for survival. No difference in survival was observed between those with and without membrane staining (24 months probability of survival: 50% and 55.4% respectively). Our results did not show any adverse prognostic effect of c-erbB-2 protein expression in our patients.

  • c-erbB-2
  • expression
  • oncogene
  • ovarian cancer
  • prognosis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.